Ad hoc announcement pursuant to Art. 53 LR
Total proceeds expected to fund global ENIGMA-TRS studies and extend cash runway beyond pivotal 12-week results, supporting development
Milan, Italy, and Morristown, NJ, USA, September 3, 2026, – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the
Ad hoc announcement pursuant to Art. 53 LR
ENIGMA-TRS 1 is Phase 3 international, one-year, randomized, double-blind, placebo-controlled study in 600+ patients; 12-week study
Ad hoc announcement pursuant to Art. 53 LR
Parties discussed information provided by Newron and changes needed by FDA to consider re-start of enrollment in ENIGMA-TRS 2 study in
Milan, Italy, and Morristown, NJ, USA – May 28, 2026, 3:30 pm CEST – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the
Ad hoc announcement pursuant to Art. 53 LR
Newron reports a pause in enrollment of new study participants in US centers of ENIGMA-TRS 2 study
Pause of enrollment limited to US
Ad hoc announcement pursuant to Art. 53 LR
Milan, Italy, and Morristown, NJ, USA – March 24, 2026, 07:00 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5
Presentations explore the role of glutamatergic modulation in treatment-resistant schizophrenia (TRS) across preclinical and clinical research
Milan, Italy, and Morristown
Ad hoc announcement pursuant to Art. 53 LR
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 Finance
The information on the following pages may be made available in the United States. By clicking on the link below, you agree that you are in the United States.
